Estrogen Impairs Adipose Tissue Expansion and Cardiometabolic Profile in Obese-Diabetic Female Rats.
Melanie Raquel Martínez-CignoniAgustí González-VicensAndrea Morán-CostoyaAna María ProenzaMagdalena GianottiAdamo ValleIsabel LladóPublished in: International journal of molecular sciences (2021)
It has been reported that 17β-estradiol (E2) can exert beneficial effects against the development of obesity, providing women with a healthier metabolic profile and conferring cardiovascular protection. However, a growing body of evidence questions this role in the context of obesity and diabetes. We focus on the adipose tissue-heart axis to address the question of whether E2 can have metabolically detrimental effects in an obese-diabetic rat model. Female Zucker Diabetic Fatty rats were used: LEAN, fa/+; SHAM, sham-operated fa/fa; OVA, ovariectomized fa/fa, and OVA+E2, ovariectomized and E2 treated fa/fa. The secretory expression profile, tissue expansion parameters and composition of visceral adipose tissue, as well as systemic and cardiac parameters related to insulin resistance, fibrosis, and inflammation were analyzed. Ovariectomy induced an attenuation of both diabetic condition and metabolic dysfunction of adipose tissue and cardiac muscle in fa/fa rats, suggesting that E2, in the context of diabetes and obesity, loses its cardioprotective role and could even contribute to greater metabolic alterations. Adipose tissue from OVA rats showed a healthier hyperplastic expansion pattern, which could help maintain tissue function, increase adiponectin expression, and decrease pro-inflammatory adipokines. These findings should be taken into account when considering hormone replacement therapy for obese-diabetic women.
Keyphrases
- adipose tissue
- insulin resistance
- type diabetes
- polycystic ovary syndrome
- high fat diet
- high fat diet induced
- metabolic syndrome
- glycemic control
- skeletal muscle
- weight loss
- wound healing
- cardiovascular disease
- oxidative stress
- left ventricular
- heart failure
- body composition
- clinical trial
- high glucose
- body mass index
- drug induced
- bone loss
- postmenopausal women
- bone mineral density
- long non coding rna
- newly diagnosed
- physical activity